We are a clinical-stage biotechnology company focused on engineering, developing, manufacturing, and ultimately commercializing a new generation of potent, ultra-long acting, scalable nutrient-stimulated hormone (NuSH) therapies for obesity and related diseases.

Discover Metsera’s innovative platforms: MINT, HALO, and MOMENTUM, enabling scalable, potent, and tolerable NuSH therapies for obesity and metabolic conditions.

1 day ago · Metsera began trading on the Nasdaq Friday under the stock symbol “MTSR.” The stock showed some pop, finishing its first day of trading at $26.50 per share, up 47.2% from the IPO price.

Jan 7, 2025 · Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future ...

3 days ago · New York City-based Metsera sold 15.28 million shares above its targeted range at $18 apiece. The company had initially marketed 17.19 million shares at a range of $15 to $17 each.

Dec 3, 2024 · MET-097为一款超长效GLP-1受体激动剂，采用HALP TM脂化修饰技术，人体半衰期约380小时（16天），为司美格鲁肽等GLP-1类产品的2-3倍，未来有望实现每月一针。 此前公布的一期临床数据显示，单次给药从0.16mg爬坡至1.6mg，多次给药从0.2mg爬坡至1.2mg，五次给药且没有采取滴定过程。 1.2mg剂量组治疗5周后减重7.5%，最后一次停药后4周减重幅度扩大到8.1%，提示药效保持时间与超长半衰期相符合。 此次启动的减重二期临床试验，计划入 …

4 days ago · Metsera, an obesity drug developer, sold nearly 15.3 million shares at $18 apiece in an offering that ranks as one of the industry’s largest since 2022, according to BioPharma Dive data. Maze, a maker of kidney disease medicines, priced more than 8.7 million shares at $16 each, exceeding the terms it had set earlier this week.

5 days ago · US-based Metsera has set its sights on a $289m public listing as the weight loss drug developer becomes one of the early biotechs to venture into the thawing IPO landscape in 2025. Metsera is offering over 17 million shares priced between $15 and $17 for its Nasdaq listing. The biotech is targeting $250.8m based on the midpoint of the price ...

Apr 18, 2024 · Founded by Population Health Partners and ARCH Venture Partners and led by former executives of The Medicines Company, Metsera is rapidly advancing a broad portfolio of oral and injectable...

6 days ago · Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to make their debuts as public companies. The New York-based firm plans to ...